UNASSIGNED: 12 Background: @entity788 is among the most lethal of @entity1 @entity5 . Data on @entity1349 rates of @entity1 treated in the community hospital setting are limited. The purpose of this retrospective data collection study was to assess the CA19-9 change during the neo-adjuvant treatment of locally advanced @entity788 @entity1 and whether this test predicts the @entity1349 ( @entity1349 ). This study was conducted within a high volume community hospital setting. METHODS: Eligibility included cytological or histological evidence of locally advanced, unresectable, and borderline resectable @entity420 , not amenable for surgical resection. Resectability was determined with EUS and CT scan/MRI and was discussed in the multi-disciplinary conference. @entity1 diagnosed before July 2009 were treated with continuous @entity1487 200mg/m(2) for 5 weeks with radiation of 1.8 Gy per daily fraction, for a total dose of 50.4 Gy over 5.5 weeks. @entity1 diagnosed after July 2009 received @entity136 400mg/m(2) intravenously (over 60 minutes) beginning on the first day of radiation therapy (before radiation), then weekly thereafter during radiation. RESULTS: Data were abstracted on 64 @entity1 (40 deceased; 24 alive) diagnosed between 6/2005 and 4/2011. The median age was 68 years (range 41-87), and 52% were male. The majority of @entity1 (97%) were diagnosed by endoscopic ultrasound (EUS) with biopsy. At diagnosis, 56 (88%) @entity1 were locally advanced unresectable (without @entity3 ) or borderline resectable; 49 of these had neoadjuvant treatment, and 13 were later resected. Median @entity1349 for all 64 @entity1 was 45.4 weeks (95% CI: 29.6-61.3), with no significant differences in @entity1349 by sex of @entity1 (p = 0.210) or smoking history (p = 0.625). Twenty-two @entity1 (34%) had >75% decreases in CA19-9 from baseline; median @entity1349 was 89.4 weeks in this group compared to 41.3 weeks in @entity1 with changes in CA19-9 <75% (p = 0.025). CONCLUSIONS: This trial demonstrates improved @entity1349 in @entity1 with locally advanced @entity788 , who had significant decrease in CA19-9 (>75% decreases in CA19-9 from baseline) in response to neo-adjuvant chemotherapy and radiation.

Decrease in CA-19-9 after neoadjuvant chemoradiation therapy to predict survival in locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic adenocarcinoma', 'pancreatic cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the pancreas'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
